Tevogen Bio (NASDAQ:TVGNW – Get Free Report) is expected to release its results before the market opens on Thursday, August 13th. Analysts expect Tevogen Bio to announce earnings of ($2.5350) per share for the quarter.
Tevogen Bio Trading Down 7.0%
Shares of TVGNW stock opened at $0.05 on Tuesday. Tevogen Bio has a fifty-two week low of $0.03 and a fifty-two week high of $0.08. The business’s 50 day moving average price is $0.05 and its 200-day moving average price is $0.04.
Tevogen Bio Company Profile
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Featured Stories
- Five stocks we like better than Tevogen Bio
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
